In light of this, the European Society of Cardiology (ESC) 2022 guidelines on cardio-oncology recommend heart failure therapy, including angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) and beta-blockers for patients who develop symptomatic cancer treatment-related cardiac dysfunction during anthracycline chemotherapy [49]. Here, ACE is linked to cancer.